{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:42:23Z","timestamp":1787341343520,"version":"build-2736575974"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12028-022-01646-5","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T21:30:31Z","timestamp":1669843831000},"page":"7-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cilostazol in Cerebral Ischemia and Subarachnoid Hemorrhage: A Promising Agent as Prevention"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4256-9812","authenticated-orcid":false,"given":"Raffaele","family":"Aspide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Castioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"1646_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-022-01637-6","author":"Adan I Qureshi","year":"2022","unstructured":"Qureshi Adan I, et al. Effect of cilostazol in animal models of cerebral ischemia and subarachnoid hemorrhage: a systematic review and meta-analysis. Neurocrit Care. 2022. https:\/\/doi.org\/10.1007\/s12028-022-01637-6.","journal-title":"Neurocrit Care"},{"issue":"5","key":"1646_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/WNF.0000000000000489","volume":"45","author":"H Chen","year":"2022","unstructured":"Chen H, Luo W, Cai X, Cai J. Cilostazol administration for subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. Clin Neuropharmacol. 2022;45(5):111\u20136. https:\/\/doi.org\/10.1097\/WNF.0000000000000489.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"1646_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s12975-018-0650-y","volume":"10","author":"H Suzuki","year":"2019","unstructured":"Suzuki H, Nakatsuka Y, Yasuda R, Shiba M, Miura Y, Terashima M, et al. Dose-dependent inhibitory effects of cilostazol on delayed cerebral infarction after aneurysmal subarachnoid hemorrhage. Transl Stroke Res. 2019;10(4):381\u20138. https:\/\/doi.org\/10.1007\/s12975-018-0650-y.","journal-title":"Transl Stroke Res"},{"issue":"2","key":"1646_CR4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s12028-021-01372-4","volume":"36","author":"AI Qureshi","year":"2022","unstructured":"Qureshi AI, Lobanova I, Huang W, Ishfaq MF, Broderick JP, Cassarly CN, et al. lessons learned from phase II and phase III trials investigating therapeutic agents for cerebral ischemia associated with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2022;36(2):662\u201381. https:\/\/doi.org\/10.1007\/s12028-021-01372-4.","journal-title":"Neurocrit Care"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-022-01646-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-022-01646-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-022-01646-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T22:55:42Z","timestamp":1676588142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-022-01646-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":4,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1007\/s12028-022-01646-5","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"6 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declare that the article content was composed in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}